Wright Investors Service Comprehensive Report for Rigel Pharmaceuticals, Inc.
27 Jan 2015
Available for Immediate Download
Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio tables (Accounting, Asset Utilization, Employee Efficiency, Fixed Charges Coverage, Leverage Analysis, Liquidity Analysis, Per-share Data and Profitability Analysis) and proprietary Wright Quality Rating analyses tables. The Wright Quality Rating, a measure of corporate risk, examines the liquidity of the stock, financial strength, profitability and corporate growth characteristics of Rigel Pharmaceuticals, Inc. There is a textual review of the financial results of Rigel Pharmaceuticals, Inc. versus Keryx Biopharmaceuticals, Inc., Cempra Inc and Progenics Pharmaceuticals, Inc. The comparative analysis of these companies compares Sales (sales, sales growth and sales per employee), Company Valuations (Price/Earnings, Price/Book, Price/Sales and 52-Week Price Change) and Financial Position (Long-term Debt/Equity). Also included for Rigel Pharmaceuticals, Inc. are the Company Description, Recent Stock Performance, Profitability Analysis, Dividend Analysis, and Key Data Items (Ticker, Major Industry, Sub-Industry, Fiscal Year End Month, Employees, Share Type, Market Capitalization, Total Shares Outstanding and Number of Closely Held Shares.) Additional research for Rigel Pharmaceuticals, Inc. includes tables with up to 10-years of history of computed ratios, sales, earnings, and security prices.